sarepta therapeutics duchenne muscular dystrophy

News

Sarepta Will Resume Gene Therapy Shipments

FDA takes U-turn on Sarepta’s Elevidys, backing Duchenne gene therapy again in ambulatory patients

On Monday, the FDA said Sarepta may resume treating ambulatory Duchenne patients with Elevidys. The recommendation comes just 10 days after the agency requested that the company halt all shipments of the one-time treatment following reports of three deaths among patients who had received a Sarepta gene therapy, including two on Elevidys.

· 11h

FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys

· 3h · on MSN

Sarepta will resume gene therapy shipments after FDA review of recent patient death

Asianet Newsable on MSN2h

Why Sarepta Therapeutics Stock Surged Nearly 48% In After-Hours Trading Today

The FDA concluded that a recent patient death in Brazil was unrelated to Sarepta’s Elevidys treatment, allowing the company ...

11h

Duchenne Muscular Dystrophy Market to Witness Significant Expansion During the Forecast Period (2025–2034) Amidst Advances in Gene Therapy and Novel Drug Approvals | DelveInsight

The Duchenne muscular dystrophy market is witnessing steady growth driven by advancements in gene therapies, exon-skipping drugs, and corticosteroid alternatives. Increasing diagnosis rates, rising ...

BioPharma Dive3d

Sarepta woes mount as Duchenne gene therapy knocked back in Europe

The European Medicines Agency determined testing failed to prove Elevidys’ benefit and issued a negative opinion that could ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results